Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in resectable EGFR mutant NSCLC
NCT02470065Phase 2Suspended
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jan 2016; status: suspended.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02470065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470065.